Finvest
EXAS Healthcare Diagnostics · Cancer testing · Diagnostics · Growth · Thesis updated July 19, 2026

Exact is widening the cancer testing funnel

01 Running thesis

The funnel is getting wider

Exact Sciences is best known for Cologuard, a stool-based colorectal cancer screening test. That product still drives the company, but the story is changing. Exact is adding Cologuard Plus, a licensed Freenome blood-based colorectal cancer test, Cancerguard for many cancers, and Oncodetect for cancer recurrence monitoring.

The bull case is that Exact can meet patients where they are. Some people will use stool tests. Some will only agree to a blood draw. Some cancer patients need help deciding on treatment, and some need monitoring after treatment. If Exact can serve each step, it can turn one lab network and one sales force into a much larger testing platform.

Q3 2025 made that case stronger. Total revenue grew 20%. Screening revenue rose 22% to $666 million, and the company screened 250,000 more people than in the year-ago quarter. That suggests Cologuard rescreens, care gap programs, and broader use are still working.

The bear case is also clear. Blood-based colorectal cancer screening may carry weaker pricing or margins than Cologuard. It may also pull some patients away from a better-known, higher-margin test instead of adding new patients. Cancerguard and Oncodetect could take years to win broad reimbursement, which could slow the path to steady profits.

Nov 2025▲The growth outlook improved after Q3 2025 revenue rose 20%, Screening grew 22% to $666 million, and Exact screened 250,000 more people year over year. The launch of Cancerguard and the Freenome blood-test license also widened the long-term product story.
Jul 2024→Initial view set the base case around Cologuard in Screening and Oncotype DX in Precision Oncology. The main question was whether Exact could turn strong test growth and its MRD and multi-cancer pipeline into sustained profitability.
02 Business model

Doctors order, labs bill

Exact makes money when a doctor orders a test, a patient completes it, Exact runs the sample in its lab, and an insurer or patient pays. That sounds simple, but each step matters. If doctors do not order, patients do not send samples or give blood, or payers cut payment, revenue can fall short.

The company reports two main revenue groups. Screening is the larger group and includes Cologuard, Cologuard Plus, the planned Freenome blood test, Cancerguard, and Riskguard. Precision Oncology includes Oncotype DX, OncoExTra, and Oncodetect.

This model can scale well if test volume grows faster than lab and sales costs. The company is showing signs of operating leverage, but it still carries the risk common to diagnostic labs: reimbursement rules, clinical guidelines, FDA review, and payer contracts can decide how much of the science turns into cash.

03 Product portfolio

From screening to monitoring

Cash cow

Cologuard and Cologuard Plus

This is the core colorectal cancer screening franchise. The shift to Cologuard Plus should help keep the product current, but payer coverage and patient completion remain critical.

Option

Freenome blood-based CRC test

Exact licensed Freenome's blood-based colorectal cancer test to reach people who refuse colonoscopy or stool tests. The open question is whether it adds volume without weakening Cologuard pricing and margins.

Steady

Oncotype DX

Oncotype DX helps guide treatment decisions in breast, prostate, and colon cancer. It anchors the Precision Oncology segment and benefits from both U.S. use and international adoption.

Option

Cancerguard

Cancerguard is Exact's newly launched multi-cancer early detection blood test. It screens for more than 50 cancers, but this market is crowded and reimbursement may take time.

Growth engine

Oncodetect

Oncodetect is a molecular residual disease test, which looks for signs of cancer left after treatment. It is seeing traction in breast and colorectal cancer, with more validation data still ahead.

Steady

Riskguard and OncoExTra

Riskguard covers hereditary cancer risk testing, while OncoExTra profiles advanced cancers. These products broaden Exact's menu beyond first-line screening.

04 Business segments

Screening pays the bills

Screening78%growing fast
Precision Oncology22%modest

Segment mix is based on Q3 2025 revenue disclosed in the earnings transcript: $666 million from Screening and $183 million from Precision Oncology. Screening is the clear revenue center, so any change in Cologuard demand or payment has a large effect.

05 Risk factors

What could go wrong

Blood test cannibalization

High impact · Medium odds

The Freenome blood test could help Exact reach people who avoid stool tests or colonoscopy. But it could also pull some patients away from Cologuard. If the blood test has worse reimbursement or lower margin, revenue could grow while profit disappoints.

We watchFDA approval, launch pricing, payer coverage, and management comments on whether blood testing is adding new patients or replacing Cologuard orders.

Cologuard Plus payer delays

High impact · Medium odds

Cologuard Plus needs strong payer contracts to protect price and volume. The internal thesis says progress with the top commercial payers is a key catalyst, with the remaining 6 of the top 10 still important to watch. Slow contracting could hurt the upgrade cycle.

We watchUpdates on Cologuard Plus coverage among the top 10 commercial payers and any change in average revenue per completed test.

MCED market takes too long

Medium impact · High odds

Cancerguard gives Exact a path into multi-cancer early detection, but this market is competitive and still needs broad clinical and payer acceptance. A test can be scientifically useful and still take years to become a major revenue source. Heavy spending before reimbursement could pressure profitability.

We watchCancerguard order volume, clinical validation data, guideline updates, and payer coverage decisions.

MRD proof and reimbursement risk

Medium impact · Medium odds

Oncodetect targets molecular residual disease, which means signs of cancer that remain after treatment. This is a promising area, but doctors and payers will want strong proof that the test changes care in useful ways. If data in triple-negative breast cancer or the next-gen MRD launch falls short, growth could slow.

We watchOncodetect validation results, triple-negative breast cancer data, and the planned 2026 MAESTRO-based next-gen MRD launch.

Profitability remains unproven

High impact · Medium odds

Exact has a long history of net losses. The Q2 2024 Form 10-Q said the company had an accumulated deficit of about $3.60 billion as of June 30, 2024. If new product spending rises faster than reimbursement and volume, the path to sustained profitability can slip again.

We watchAdjusted EBITDA margin, net loss trends, R&D spending, and cash flow after major product launches.
06 Quick answers

In one breath

What does Exact Sciences do?

Exact Sciences sells cancer screening and diagnostic lab tests. Its best-known product is Cologuard for colorectal cancer screening, and it also sells Oncotype DX tests that help guide cancer treatment.

Why does Cologuard matter so much to EXAS?

Cologuard sits inside the Screening segment, which produced $666 million of revenue in Q3 2025. That was the clear majority of the company's disclosed segment revenue for the quarter.

What is the Freenome test and why is it important?

The Freenome test is a blood-based colorectal cancer screening test licensed by Exact. It could reach people who avoid stool tests, but investors need to watch whether it adds new demand or takes volume from Cologuard.

Is Exact Sciences profitable?

The company has a history of losses and said in its Q2 2024 Form 10-Q that it may not achieve or sustain profitability. The growth case depends on higher test volume and better operating leverage over time.